These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26735920)

  • 1. Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
    Morizot G; Jouffroy R; Faye A; Chabert P; Belhouari K; Calin R; Charlier C; Miailhes P; Siriez JY; Mouri O; Yera H; Gilquin J; Tubiana R; Lanternier F; Mamzer MF; Legendre C; Peyramond D; Caumes E; Lortholary O; Buffet P
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004304. PubMed ID: 26735920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children.
    Apa H; Devrim İ; Bayram N; Deveci R; Demir-Özek G; Cartı ÖU
    Turk J Pediatr; 2013; 55(4):378-83. PubMed ID: 24292030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
    Sundar S; Jha TK; Thakur CP; Mishra M; Singh VR; Buffels R
    Am J Trop Med Hyg; 2002 Feb; 66(2):143-6. PubMed ID: 12135284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis.
    Santos MA; Marques RC; Farias CA; Vasconcelos DM; Stewart JM; Costa DL; Costa CH
    Rev Soc Bras Med Trop; 2002; 35(6):629-33. PubMed ID: 12612746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of visceral leishmaniasis in children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
    Vigna E; De Vivo A; Gentile M; Morelli R; Lucia E; Mazzone C; Recchia AG; Vianelli N; Morabito F
    Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
    Dilber E; Erduran E; Işik Y
    Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis.
    Zhao S; Zhang D; Li L; Mao Q
    Am J Trop Med Hyg; 2011 Dec; 85(6):1035-7. PubMed ID: 22144439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK; Sah AK; Shah DK; Sah P
    JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
    Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
    Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
    Murray HW
    Int J Infect Dis; 2000; 4(3):158-77. PubMed ID: 11179920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison.
    Cota GF; de Sousa MR; Fereguetti TO; Rabello A
    PLoS Negl Trop Dis; 2013; 7(5):e2195. PubMed ID: 23658850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.
    Sundar S; Murray HW
    J Infect Dis; 1996 Mar; 173(3):762-5. PubMed ID: 8627049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of infantile visceral leishmaniasis].
    Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
    Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Mediterranean visceral leishmaniasis.
    Gradoni L; Bryceson A; Desjeux P
    Bull World Health Organ; 1995; 73(2):191-7. PubMed ID: 7743590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.